Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10327302" target="_blank" >RIV/00064165:_____/16:10327302 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/16:00091332 RIV/00216208:11110/16:10327302 RIV/65269705:_____/16:00065609

Výsledek na webu

<a href="http://dx.doi.org/10.1186/s12969-016-0099-z" target="_blank" >http://dx.doi.org/10.1186/s12969-016-0099-z</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s12969-016-0099-z" target="_blank" >10.1186/s12969-016-0099-z</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration

Popis výsledku v původním jazyce

Background: There is a lack of published evidence on the importance of methotrexate (MTX) dose and route of administration on both its efficacy and adverse events in children with Juvenile Idiopathic Arthritis (JIA). We aimed to document our clinical practice based on the treat-to-target approach in order to support the concept that better therapeutic effect achieved with an optimal dose of parenteral MTX is associated with clinically acceptable adverse effects comparable to those reported for oral treatment. Methods: Study inclusion criteria were indication of new MTX therapy for active arthritis in confirmed JIA patients younger than 18 years. Eligible patients were evaluated prospectively every 3 months for 1 year using standardized instruments for treatment response (American College of Rheumatology Pediatric (ACRPedi) response, Juvenile Arthritis Disease Activity Score (JADAS) 71, Clinically Inactive Disease (CID)) and adverse events (laboratory monitoring, Methotrexate Intolerance Severity Score (MISS)). MTX responders had to achieve at least ACRPedi 70 response. MTX intolerance was defined by MISS >=6.

Název v anglickém jazyce

Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration

Popis výsledku anglicky

Background: There is a lack of published evidence on the importance of methotrexate (MTX) dose and route of administration on both its efficacy and adverse events in children with Juvenile Idiopathic Arthritis (JIA). We aimed to document our clinical practice based on the treat-to-target approach in order to support the concept that better therapeutic effect achieved with an optimal dose of parenteral MTX is associated with clinically acceptable adverse effects comparable to those reported for oral treatment. Methods: Study inclusion criteria were indication of new MTX therapy for active arthritis in confirmed JIA patients younger than 18 years. Eligible patients were evaluated prospectively every 3 months for 1 year using standardized instruments for treatment response (American College of Rheumatology Pediatric (ACRPedi) response, Juvenile Arthritis Disease Activity Score (JADAS) 71, Clinically Inactive Disease (CID)) and adverse events (laboratory monitoring, Methotrexate Intolerance Severity Score (MISS)). MTX responders had to achieve at least ACRPedi 70 response. MTX intolerance was defined by MISS >=6.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FG - Pediatrie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT14149" target="_blank" >NT14149: Kvalita života dětí s juvenilní idiopatickou artritidou: význam nelékařských profesí v komplexním léčebném programu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pediatric Rheumatology

ISSN

1546-0096

e-ISSN

—

Svazek periodika

14

Číslo periodika v rámci svazku

June

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

—

Kód UT WoS článku

000377783400001

EID výsledku v databázi Scopus

2-s2.0-84974828478